LYON, France — Reportlinker.com announces that a new market research report related to the worldwide pharmaceutical industry is available in its catalogue.
Organon: PharmaVitae Profile
To order that report:
www.reportlinker.com/p063020/PRBW-Organon-Profile.html
For more information, contact Nicolas by email nbo@reportlinker.com , or by phone 33 4 37 65 17 03.
Description
Introduction
This analysis examines the historical and forecast performance for Organon in the ethical pharmaceutical sector.
The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Related Results
Missouri announces settlement with anti-depressant drug maker
Teva Announces Final Approval of Mirtazapine Orally Disintegrating Tablets
Pittsburgh Post-Gazette Business Briefs Column. prozac.
Missouri Atty. General announces settlement with drug maker Organon
Akzo confirms latest chemicals review; steps up biotechnology
An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Organon’s performance against key rivals in the ethical pharmaceutical sector.
Evaluate Organon’s prospects out to 2012, following the recent $14.8 billion acquisition bid by US-based Big Pharma Schering-Plough.
Learn how Organon’s innovative late-stage pipeline, from which six new products are set to launch, is central to the company’s healthy outlook.
Table of content
CHAPTER 1 EXECUTIVE SUMMARY
Key findings
Historical and forecast ethical sales performance
Therapeutic strategy
Launch and expiry outlook
Externalization, geographic and molecule type strategies
Externalization strategy
Geographic strategy
Molecule type strategy
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
CHAPTER 2 CORPORATE HISTORY
Key findings
Background
Key corporate developments
Imminent IPO diverted following Schering-Plough’s entry into the fray
M&A history
M&A strategy
Organon M&A
Current corporate structure
Current management team
CHAPTER 3 HISTORICAL PERFORMANCE
Key findings
Introduction
Revenue and growth rate analysis, 2001-06
Revenue and growth rate vs. peer set
Product analysis, 2001-06
Growth drivers
NuvaRing
Puregon
Growth resistors
Remeron
Livial
Operating revenue and cost analysis, 2001-06
Operating revenue/cost analysis
CHAPTER 4 FORECAST PERFORMANCE
Key findings
Introduction
Revenue and growth rate, 2006-12
Product analysis, 2006-12
Growth drivers
Asenapine
Sugammadex
Org 50081 (insomnia)
NuvaRing
Implanon
Growth resistors
Esmeron
Livial
Therapy area analysis, 2006-12
Central nervous system
Urology & sexual health
Therapy area focus
Launches and expiries analysis, 2006-12
Launch portfolio
Core portfolio
Expiry portfolio
Launch/core/expiry configuration
Externalization analysis, 2006-12
Geographic analysis, 2006-12
Molecule type analysis, 2006-12
CHAPTER 5 KEY PRODUCTS AND COMPETITORS
Key findings
Overview
Women’s health
NuvaRing
CHAPTER 6 APPENDIX
IMS vs. company-reported data reconciliation
References
Abbreviations
Exchange rates
List of Tables
Table 1: Organon Biosciences Executive Committee
Table 2: Peer set overview
Table 3: Operating revenue/cost analysis ($m), 2001-06
Table 4: Operating cost ratio analysis (% of total revenues), 2001-06
Table 5: Product portfolio overview, sales ($m), 2006-12
Table 6: Therapy area overview, sales ($m), 2006-12
Table 7: Launch portfolio overview, sales ($m), 2006-12
Table 8: Core portfolio overview, sales ($m), 2006-12
Table 9: Expiry portfolio overview, sales ($m), 2006-12
Table 10: Externally developed portfolio ($m), 2006-12
Table 11: Molecule type overview, sales ($m), 2006-12
Table 12: Key products overview
Table 13: NuvaRing: overview
Table 14: NuvaRing: sales forecast ($m), 2006-12
Table 15: NuvaRing: news flow
Table 16: Organon’s non-DTC marketing expenditure in 2006
Table 17: Top 10 contraceptive products in 2006 (7MM)
Table 18: Puregon/Follistim: overview
Table 19: Puregon/Follistim: sales forecast ($m), 2006-12
Table 20: Puregon/Follistim: news flow
Table 21: Implanon: overview
Table 22: Implanon: sales forecast ($m), 2006-12
Table 23: Implanon: news flow
Table 24: NOMAC/E2: overview
Table 25: NOMAC/E2: sales forecast ($m), 2006-12
Table 26: NOMAC/E2: news flow
Table 27: Org 32686: overview
Table 28: Org 32686: sales forecast ($m), 2006-12
Table 29: Org 32686: news flow
Table 30: Asenapine: overview
Table 31: Asenapine: sales forecast ($m), 2006-12
Table 32: Asenapine: news flow
Table 33: Sugammadex: overview
Table 34: Sugammadex: sales forecast ($m), 2006-12
Table 35: Sugammadex: news flow
Table 36: Remeron: overview
Table 37: Remeron: sales forecast ($m), 2006-12
Table 38: Remeron: news flow
Table 39: Org 50081 (insomnia): overview
Table 40: Org 50081 (insomnia): sales forecast ($m), 2006-12
Table 41: Org 50081 (insomnia): news flow
Table 42: Esmeron: overview
Table 43: Esmeron/Zemuron: sales forecast ($m), 2006-12
Table 44: Esmeron/Zemuron: news flow
Table 45: Organon’s R&D pipeline (Phase I-registration)
Table 46: Exchange rates, 2006
More market research reports? Go to http://www.reportlinker.com
http://market-research.typepad.com/agricultural_chemicals/
COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning